Polycystic Ovary Syndrome (PCOS) 2023-Evidence based Guidelines for the Assessment and Management!

Free view: for full session please subscribe to my full lecture series
You can whats app me on 00971557434794 or email me at [e-mail]
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive-aged women, with impacts across the lifespan from adolescence to post menopause.
PCOS prevalence is between 10% and 13% as confirmed in the guideline process.
PCOS aetiology is complex; clinical presentation is heterogeneous with reproductive, metabolic, and psychological features.
Women internationally experience delayed diagnosis and dissatisfaction with care.
Clinical practice in the assessment and management of PCOS remains inconsistent, with ongoing key evidence-practice gaps.
Following on from the 2018 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, independently evaluated as high quality, this extensive update integrates current literature with previous systematic reviews and extends to new clinical questions prioritized by consumers.
Ultimately, we aim to update, extend and translate rigorous, comprehensive evidence-based guidelines for diagnosis, assessment and treatment, to improve the lives of those with PCOS worldwide.